Table 1.

Further hemodynamic description of both experimental PAH models

	MCT (n = 5)	MCT + palbociclib (n = 5)	Su/Hox (n = 8)	Su/Hox + palbociclib (n = 7)
BW [g]	452 ± 30 (pre)	420 ± 37 (pre)	365 ± 20 (pre)	363 ± 16 (pre)
	451 ± 37 (post)	405 ± 33 (post)	391 ± 19 (post)	362 ± 28 (post)
HR [bpm]	342 ± 34 (pre)	342 ± 39 (pre)	349 ± 28 (pre)	368 ± 16 (pre)
	339 ± 40 (post)	339 ± 24 (post)	337 ± 17 (post)	317 ± 42** (post)
SVI [µl] per 100 g BW	46.8 ± 4.5 (pre)	49.7 ± 7.7 (pre)	35.5 ± 4.6 (pre)	35.3 ± 3.2 (pre)
	34.7 ± 9.9§ (post)	55.4 ± 10.7## (post)	33.3 ± 4.9 (post)	54.9 ± 11.9****,#### (post)
CI [ml/min] per 100 g BW	15.9 ± 1.9 (pre)	16.7 ± 1.5 (pre)	12.4 ± 1.5 (pre)	12.8 ± 1.1 (pre)
	11.9 ± 3.9§ (post)	17.7 ± 2.4# (post)	11.2 ± 1.7 (post)	16.6 ± 3.5 **,### (post)
RVID [mm]	4.2 ± 0.2 (pre)	4.1 ± 0.3 (pre)	4.7 ± 0.3 (pre)	4.7 ± 0.3 (pre)
	6.0 ± 0.8§§§§ (post)	4.5 ± 0.4### (post)	5.3 ± 0.5§§ (post)	4.3 ± 0.5### (post)
TAPSE [mm]	2.2 ± 0.2 (pre)	2.4 ± 0.1 (pre)	1.49 ± 0.07 (pre)	1.46 ± 0.08 (pre)
	1.8 ± 0.3§ (post)	2.3 ± 0.2## (post)	1.3 ± 0.1§§ (post)	2.1 ± 0.1 ****,#### (post)

Data, i.e., before (pre) and at the end of the treatment (post), are presented as mean ± SD and statistical analysis was performed using one-way ANOVA with Newman–Keuls post-hoc test for multiple comparisons. MCT rat model: ^§p < 0.05, ^§§§§p  < 0.0001 for post-versus pre-treatment of MCT; ^#p  < 0.05, ^##p < 0.01, ^###p < 0.001 for post-treatment MCT  +  Palbociclib versus MCT. Su/Hox model: ^§§p < 0.01 for post-versus pre-treatment of Su/Hox; ^**p < 0.01, ^****p  < 0.0001 for post-versus pre-treatment of Su/Hox + Palbociclib; ^###p  < 0.001, ^####p  < 0.0001 for post-treatment Su/Hox  +  Palbociclib versus Su/Hox.

BW body weight, HR heart rate, SVI stroke volume index, CI cardiac index, RVID right ventricular internal diameter, TAPSE tricuspid annular plane systolic excursion. Source data are provided as a Source